With clinical data showing clear signals of efficacy of PROTACs, increasing number of candidates accelerated towards clinical development and the rise of molecular glues unlike ever seen before, it’s certainly an exciting time for the field of targeted protein degradation.

In the context of rapid progress and mounting desire to transform degrader tools into transformative therapies, the 5^th Annual Targeted Protein Degradation (TPD) Summit will reunite large pharma, innovative biotechs and pioneering academics to discuss the full and comprehensive range of next generation protein degrading technologies to achieve efficient degradation of a broad range of disease-causing targets.

From optimizing PKPD, to overcoming innate and acquired resistance and enabling brain barrier penetration, this is your most comprehensive guide to addressing the most unique challenges of next generation targeted protein degraders to power your strategies and pipelines towards achieving your 2022 milestones.